These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
601 related articles for article (PubMed ID: 32448671)
1. One-Year Outcomes of Living Related Kidney Transplant in Patients With Preformed HLA Donor-Specific Antibodies: A Single-Center Experience in Malaysia. Jalalonmuhali M; Ng KP; Mohd Shariff NH; Lee YW; Wong AH; Gan CC; Lim SK Transplant Proc; 2020; 52(6):1718-1722. PubMed ID: 32448671 [TBL] [Abstract][Full Text] [Related]
3. Frequent development of subclinical chronic antibody-mediated rejection within 1 year after renal transplantation with pre-transplant positive donor-specific antibodies and negative CDC crossmatches. Yamanaga S; Watarai Y; Yamamoto T; Tsujita M; Hiramitsu T; Nanmoku K; Goto N; Takeda A; Morozumi K; Katayama A; Saji H; Uchida K; Kobayashi T Hum Immunol; 2013 Sep; 74(9):1111-8. PubMed ID: 23792054 [TBL] [Abstract][Full Text] [Related]
4. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience. Olszowska-Zaremba N; Gozdowska J; Zagożdżon R Transpl Immunol; 2022 Oct; 74():101672. PubMed ID: 35868613 [TBL] [Abstract][Full Text] [Related]
5. The Impact of Donor-Specific Anti-Human Leukocyte Antigen (HLA) Antibody Rebound on the Risk of Antibody Mediated Rejection in Sensitized Kidney Transplant Recipients. Lee KW; Park JB; Cho CW; Lee N; Yoo H; Kim K; Park H; Kang ES; Huh W; Kim S Ann Transplant; 2017 Mar; 22():166-176. PubMed ID: 28348361 [TBL] [Abstract][Full Text] [Related]
6. Perioperative Desensitization Improves Outcomes Among Crossmatch Positive Recipients of Deceased Donor Renal Transplants. Sharma A; King A; Kumar D; Behnke M; McDougan F; Kimball PM Prog Transplant; 2016 Jun; 26(2):157-61. PubMed ID: 27207404 [TBL] [Abstract][Full Text] [Related]
7. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience. Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J Clin Transpl; 2014; ():223-30. PubMed ID: 26281149 [TBL] [Abstract][Full Text] [Related]
8. Impact of Positive Donor-Specific HLA Antibodies Crossmatch on Graft Survival in ABO-Incompatible Liver-Kidney Transplantation: A Case Report. Hsieh CE; Yang Y; Lin KH; Chen CC; Ko CJ; Hsu YL; Lin CC; Hung YJ; Lin PY; Wang SH; Chen YL Transplant Proc; 2018 Dec; 50(10):4008-4011. PubMed ID: 30522859 [TBL] [Abstract][Full Text] [Related]
9. Outcome of desensitization in human leukocyte antigen- and ABO-incompatible living donor kidney transplantation: a single-center experience in more than 100 patients. Al Meshari K; Pall A; Chaballout A; El Gamal H; Al Mana H; Humaidan H; Alzayer F; Al Talhi M Transplant Proc; 2013 May; 45(4):1423-6. PubMed ID: 23726587 [TBL] [Abstract][Full Text] [Related]
11. Long-term results of desensitization protocol with and without rituximab in sensitized kidney transplant recipients. Green H; Nesher E; Aizner S; Israeli M; Klein T; Zakai H; Rahamimov R; Rozen-Zvi B; Mor E Clin Transplant; 2019 Jun; 33(6):e13562. PubMed ID: 30941818 [TBL] [Abstract][Full Text] [Related]
12. Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis. Klein K; Süsal C; Schäfer SM; Becker LE; Beimler J; Schwenger V; Zeier M; Schemmer P; Macher-Goeppinger S; Scherer S; Opelz G; Morath C Atheroscler Suppl; 2013 Jan; 14(1):199-202. PubMed ID: 23357165 [TBL] [Abstract][Full Text] [Related]